Revolution Medicines (RVMD) is trading higher as investors digest newly released topline data from the pivotal Phase 3 RASolute 302 study of daraxonrasib (RMC-6236) in previously treated metastatic pancreatic ductal adenocarcinoma. The company reported a large overall-survival benefit versus chemotherapy, a readout that can materially change the probability of eventual approval and the projected peak-sales outlook for its lead RAS(ON) program. (globenewswire.com)

RASolute 302 delivered a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for the chemotherapy control, with a hazard ratio of 0.40 and p<0.0001. The magnitude of the survival separation is driving the move, because overall survival is typically viewed as the most clinically meaningful endpoint in metastatic pancreatic cancer trials. (tradingview.com)

The Phase 3 win strengthens the company’s regulatory path and supports expectations that daraxonrasib could become a new standard option in the post-treatment metastatic PDAC setting, where outcomes are poor and effective therapies are limited. Management said it plans to submit the data to global regulatory authorities, setting the stage for the next major catalyst to be timing and details of regulatory filings and review. (globenewswire.com)

Near-term, traders will focus on when full data are presented and whether efficacy and safety details reinforce the topline release, as well as any updated guidance on filing timelines. Separately, the next earnings event (currently tracked for May 2026) can shift sentiment around burn rate, runway, and pace of clinical spend as the company advances additional RAS programs. (investing.com)